CDK4 and liposarcoma: The evidence regarding MDM2 inhibitors as a treatment for liposarcoma is limited to preclinical data and a phase I trial [81,82], but the double inhibition by MDM2 and CDK4 might be synergic, which would be worth evaluating [83].